Health
Exploring Ongoing Trials With 177Lu-PSMA-617 in Prostate Cancer – Targeted Oncology
Arun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.
Arun Azad, MBBS, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne, and chair of the ANZUP Cancer Trials Group Translational, discusses ongoing studies of lutetium-177-PSMA (177Lu-PSMA-617) radionuclide in patients with prostate cancer.
Theres the UpFrontPSMA trial (NCT04343885), a randomized phase 2 study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel alone in patients with metastatic hormone-naïve prostate cancer that is recruiting right now….
-
General20 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Business24 hours agoUp 20% in 2 days, are Codan shares a buy, hold or sell?
-
General18 hours agoEveryday AI use brings a hidden climate cost
-
Noosa News23 hours agoBoat crash in Helensvale on the Gold Coast leaves man with life-threatening burns and another one injured